UMIN000049225
Rechallenge of afatinib for EGFR mutated non-small cell lung cancer previously treated with osimertinib
Shinshu University School of Medicine·University Hospital Medical Information Network·drugEnrolling by invitation
Study focus
- Disease/Condition
- Non-small cell lung cancer
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Shinshu University School of Medicine
- Location
- Japan
Timeline & enrollment
- Phase
- N/A
- Start date
- Oct 18, 2022
- End date
- N/A
ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- University Hospital Medical Information Network
- Trial ID
- UMIN000049225
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for UMIN000049225 through Pure Global AI's free database. This phase not specified trial is sponsored by Shinshu University School of Medicine and is currently Enrolling by invitation. The study focuses on Non-small cell lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.